Lannett Company Inc

Lannett Company Inc

Health CarePharmaceuticals & Biotechnology
  • Price (USD)6.70
  • Today's Change-0.16 / -2.33%
  • Shares traded268.75k
  • 1 Year change-33.33%
  • Beta1.1496
Data delayed at least 15 minutes, as of Jan 15 2021 21:10 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

  • Revenue in USD (TTM)544.88m
  • Net income in USD-27.71m
  • Incorporated1991
  • Employees954.00
  • Location
    Lannett Company Inc9000 State RdPHILADELPHIA 19136-1615United StatesUSA
  • Phone+1 (215) 333-9000
  • Fax+1 (302) 636-5454
  • Websitehttps://www.lannett.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Xeris Pharmaceuticals Inc15.09m-102.37m263.00m172.00--17.48--17.42-3.10-3.100.41950.30720.1011--2.3174,722.77-68.59---80.71--50.37---678.18--5.83-18.390.8928--10.43---109.02------
LogicBio Therapeutics Inc2.91m-37.19m265.74m41.00--8.88--91.26-1.60-1.600.12520.94110.0535----71,024.39-68.30---74.85-------1,276.99-----55.300.309-------127.73------
Oncternal Therapeutics Inc2.52m-18.82m266.46m11.00--7.77--105.66-1.14-1.140.15030.70260.1038----229,272.70-77.46-81.90-109.83-136.40-----746.39-5,751.42----0.0188------11.01------
Tyme Technologies Inc0.00-28.36m266.85m18.00--18.40-----0.2333-0.23330.000.11140.00----0.00-142.92---192.92-------------13.180.0119------33.30------
Gritstone Oncology Inc3.57m-105.85m267.15m177.00--3.35--74.77-2.87-2.870.09671.910.0216--23.9020,534.48-63.93---73.96-------2,962.52------0.00--267.73---45.79------
9 Meters Biopharma Inc0.00-65.44m267.50m8.00--54.53-----0.9605-0.96050.000.02420.00----0.00-551.76-306.57-26,912.24---------521.25---44.360.2589-------11.95------
Osmotica Pharmaceuticals PLC203.26m-51.36m272.25m379.00--1.82--1.34-0.924-0.9243.512.390.44123.267.33536,314.20-11.15---13.04--60.75---25.27--2.811.060.5928---8.98---146.99------
Lannett Company, Inc.544.88m-27.71m279.39m954.00--0.88189.240.5128-0.72-0.7213.877.600.4732.603.49571,154.10-2.41-3.22-2.91-3.7727.2142.50-5.09-7.251.300.7760.6904---16.736.0587.74--8.07--
Vyne Therapeutics Inc16.71m-253.89m280.36m180.00--5.66--16.78-3.19-3.190.17910.2950.1636----417,675.00-248.59---295.88--94.86---1,519.63--3.95-154.140.40---100.00---43.27------
RenovaCare Inc0.00-8.18m280.97m2.00--32.71-----0.0936-0.09360.000.09830.00----0.00-71.06-47.25-75.13-50.26------------0.00-------58.34------
Verrica Pharmaceuticals Inc0.00-37.35m281.68m17.00--7.19-----1.50-1.500.001.510.00----0.00-47.89---66.30-------------29.740.4717-------36.61------
CorMedix Inc.208.29k-21.24m284.05m30.00--8.04--1,363.73-0.7875-0.78750.00781.100.00570.66641.336,943.00-57.62-109.70-66.25-142.186.99-6.35-10,199.69-8,065.868.40--0.00---34.098.40-62.27--7.56--
Checkmate Pharmaceuticals Inc-100.00bn-100.00bn285.33m22.00--2.11----------6.27----------------------------0.00-------39.48------
Chromadex Corp56.90m-22.68m288.55m110.00--14.76--5.07-0.3763-0.37630.94030.31641.412.2617.90517,281.80-56.31-52.15-80.26-74.6358.5549.87-39.86-61.881.51-471.520.0054--46.6924.763.51--24.37--
Vincerx Pharma Inc-100.00bn-100.00bn293.67m----2.75----------7.63----------------------------0.0157-------8,144.14------
Data as of Jan 15 2021. Currency figures normalised to Lannett Company Inc's reporting currency: US Dollar USD

Institutional shareholders

61.79%Per cent of shares held by top holders
HolderShares% Held
Telemus Capital LLCas of 30 Sep 20207.69m18.45%
BlackRock Fund Advisorsas of 30 Sep 20204.78m11.46%
JPMorgan Investment Management, Inc.as of 30 Sep 20202.71m6.50%
The Vanguard Group, Inc.as of 30 Sep 20202.22m5.33%
LSV Asset Managementas of 30 Sep 20202.01m4.82%
D. E. Shaw & Co. LPas of 30 Sep 20201.80m4.32%
Renaissance Technologies LLCas of 30 Sep 20201.70m4.07%
SSgA Funds Management, Inc.as of 30 Sep 20201.29m3.09%
Dimensional Fund Advisors LPas of 30 Sep 2020949.73k2.28%
JPMorgan Chase Bank, NA (Investment Management)as of 30 Sep 2020617.32k1.48%
More ▼
Data from 30 Sep 2020 - 30 Sep 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.